key: cord-1053416-ov4r3ple
authors: Ortoleva, Jamel
title: Consider Adjunctive Ketamine in Mechanically Ventilated COVID-19 Patients
date: 2020-04-28
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2020.04.037
sha: fb312b448327c0b83635e5edea6e7dff24cf0790
doc_id: 1053416
cord_uid: ov4r3ple

nan

Jamel Ortoleva, MD 1 1. Tufts Medical Center Department of Anesthesiology and Perioperative Medicine 6 th floor, Ziskind building 800 Washington Street Boston, MA, 02111. Email: jortoleva@tuftsmedicalcenter.org

The author reports no conflicts of interest relevant to this work.

The 2019 novel coronavirus has infected patients in nearly every country and resulted in the deaths of over forty thousand people worldwide. 1 The predominant cause of critical illness and death in coronavirus patients is acute respiratory distress syndrome (ARDS). 2 Another important cause which is frequently present with ARDS is cytokine storm can result in vasodilatory shock and multiorgan dysfunction. 3 The hyperinflammation associated with cytokine storm is similar to that found in secondary haemophagocytic lymphohistiocytosis (HLH). 3 Elevated levels of molecules including but not limited to interleukin (IL) 2, 6 and 7 are found in patients suffering from this hyperinflammatory response. 3 Immune modulation of this cytokine storm with the IL-6 inhibitors sarilumab and tocilizumab is an approach that is gaining interest and an active area of investigation. 4, 5 Anesthesiologists are in a unique position to blend a unique skill set of knowledge in mechanical ventilation, hemodynamic management, procedural expertise, and pharmacology to treat the most critically ill COVID-19 patients.

A popular agent with a recent resurgence, ketamine, is a phencyclidine dissociative amnestic that acts as an antagonist to the N-methyl-D-aspartate receptor. 6 The use of ketamine has gained significant interest in sedation and anesthesia in a myriad of settings. It is well known that ketamine increases blood pressure and heart rate by releasing endogenous catecholamines, causes bronchodilation, is a potent analgesic and sedative, and has minimal effects on respiratory status. 6 It would be exciting to study ketamine as part of a sedation regimen, in double blindrandomized fashion, for patients with respiratory failure due to COVID-19. If the antiinflammatory effects it confers reduce the risk of cytokine storm and the negative effects of inflammation, there may be a morbidity and mortality benefit. A new use for this cost-effective, safe, and readily available medication could revolutionize the efforts to treat this global pandemic.

World Health Organization Situation Report

Clinical Course and Risk factors for Mortality of Adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients with COVID-19

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Severe COVID-19 Pneumonia (COVACTA)

Ketamine in adult cardiac surgery and the cardiac surgery Intensive Care Unit: an evidence-based clinical review

Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and metaanalysis

Ketamine attenuates post-operative cognitive dysfunction after cardiac surgery